Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route (Ascending) Package Effective Date Package Discontinuation Date Status
63629-4023-08 63629-4023 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Aug. 25, 2011 In Use
63629-4023-09 63629-4023 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral May 20, 2011 In Use
63629-4788-01 63629-4788 Estradiol Estradiol 2.0 mg/1 Hormonal Therapy Estrogen Oral Dec. 22, 2021 In Use
63629-4788-02 63629-4788 Estradiol Estradiol 2.0 mg/1 Hormonal Therapy Estrogen Oral Dec. 22, 2021 In Use
63629-4788-03 63629-4788 Estradiol Estradiol 2.0 mg/1 Hormonal Therapy Estrogen Oral Dec. 22, 2021 In Use
63629-4788-04 63629-4788 Estradiol Estradiol 2.0 mg/1 Hormonal Therapy Estrogen Oral Dec. 22, 2021 In Use
63629-4788-05 63629-4788 Estradiol Estradiol 2.0 mg/1 Hormonal Therapy Estrogen Oral Oct. 9, 2017 In Use
63629-5083-01 63629-5083 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Aug. 29, 2013 In Use
63629-5083-02 63629-5083 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Feb. 8, 2022 In Use
63629-5083-03 63629-5083 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Feb. 11, 2016 In Use
61919-0733-90 61919-0733 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Jan. 18, 2019 In Use
63629-9429-01 63629-9429 Abiraterone acetate Abiraterone Acetate 250.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral Aug. 23, 2022 In Use
63629-9430-01 63629-9430 Abiraterone acetate Abiraterone Acetate 500.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral Aug. 23, 2022 In Use
64380-0970-25 64380-0970 Hydrocortisone Hydrocortisone 5.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Sept. 25, 2020 In Use
64380-0971-06 64380-0971 Hydrocortisone Hydrocortisone 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Sept. 25, 2020 In Use
64380-0972-06 64380-0972 Hydrocortisone Hydrocortisone 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Sept. 25, 2020 In Use
64679-0793-01 64679-0793 imatinib mesylate Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan. 17, 2019 In Use
64679-0793-02 64679-0793 imatinib mesylate Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan. 17, 2019 In Use
64679-0793-03 64679-0793 imatinib mesylate Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan. 17, 2019 In Use
64679-0794-01 64679-0794 imatinib mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan. 17, 2019 In Use
64679-0794-02 64679-0794 imatinib mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan. 17, 2019 In Use
64679-0794-03 64679-0794 imatinib mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan. 17, 2019 In Use
64980-0276-06 64980-0276 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Feb. 1, 2017 In Use
64980-0277-12 64980-0277 Capecitabine Capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Feb. 1, 2017 In Use
64980-0333-05 64980-0333 Temozolomide Temozolomide 5.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral March 17, 2017 In Use
64980-0333-14 64980-0333 Temozolomide Temozolomide 5.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral March 17, 2017 In Use
64980-0334-05 64980-0334 Temozolomide Temozolomide 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral March 17, 2017 In Use
64980-0334-14 64980-0334 Temozolomide Temozolomide 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral March 17, 2017 In Use
64980-0335-05 64980-0335 Temozolomide Temozolomide 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral March 17, 2017 In Use
64980-0335-14 64980-0335 Temozolomide Temozolomide 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral March 17, 2017 In Use
64980-0336-05 64980-0336 Temozolomide Temozolomide 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral March 17, 2017 In Use
64980-0336-14 64980-0336 Temozolomide Temozolomide 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral March 17, 2017 In Use
64980-0337-05 64980-0337 Temozolomide Temozolomide 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral March 17, 2017 In Use
64980-0337-14 64980-0337 Temozolomide Temozolomide 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral March 17, 2017 In Use
64980-0338-05 64980-0338 Temozolomide Temozolomide 250.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral March 17, 2017 In Use
65162-0843-06 65162-0843 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral March 10, 2017 Feb. 1, 2024 No Longer Used
65162-0844-06 65162-0844 Capecitabine Capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral March 10, 2017 Feb. 1, 2024 No Longer Used
65162-0844-16 65162-0844 Capecitabine Capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral March 10, 2017 Feb. 1, 2024 No Longer Used
65162-0844-50 65162-0844 Capecitabine Capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral March 10, 2017 Feb. 1, 2024 No Longer Used
65597-0402-20 65597-0402 pexidartinib Turalio 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor CSF1R, KIT, FLT3 Oral Aug. 2, 2019 Jan. 31, 2024 No Longer Used
65597-0402-28 65597-0402 pexidartinib Turalio 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor CSF1R, KIT, FLT3 Oral Aug. 2, 2019 Jan. 31, 2024 No Longer Used
65597-0504-04 65597-0504 QUIZARTINIB VANFLYTA 17.7 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FLT3 Oral July 20, 2023 In Use
65597-0504-28 65597-0504 QUIZARTINIB VANFLYTA 17.7 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FLT3 Oral July 20, 2023 In Use
65597-0511-04 65597-0511 QUIZARTINIB VANFLYTA 26.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FLT3 Oral July 20, 2023 In Use
65597-0511-28 65597-0511 QUIZARTINIB VANFLYTA 26.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FLT3 Oral July 20, 2023 In Use
67296-0140-01 67296-0140 Prednisone Prednisone 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral April 22, 2020 In Use
67296-0140-02 67296-0140 Prednisone Prednisone 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral June 24, 2011 In Use
67296-0140-03 67296-0140 Prednisone Prednisone 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral April 22, 2020 In Use
67296-0140-09 67296-0140 Prednisone Prednisone 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral April 22, 2020 In Use
67296-0247-01 67296-0247 Prednisone Prednisone 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Feb. 13, 2003 In Use

Found 10,000 results in 9 milliseconds — Export these results